Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1997; 30:1813-1818
© 1997 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tse, H.
Right arrow Articles by Cheng, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tse, H.
Right arrow Articles by Cheng, G

Relation between mitral regurgitation and platelet activation

HF Tse, CP Lau, and G Cheng

Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong.

OBJECTIVES: This study sought to examine the effect of mitral regurgitation (MR) on platelet activation in patients with mitral valve prolapse (MVP) or rheumatic MR. BACKGROUND: MVP and rheumatic MR are associated with an increased incidence of thromboembolic events. Although the underlying causes are not clear, increased platelet activation has been suggested as one of the pathogenic mechanisms. Results of previous studies that have investigated the relation between MVP and platelet activation are controversial. Whether the presence of MR in patients with mitral valve disease is associated with platelet activation remains unclear. METHODS: We studied platelet activation by measuring the plasma level of platelet factor 4 (PF4) and beta-thromboglobulin (BTG) in 16 patients with MVP, 12 patients with rheumatic MR and 25 control subjects. A detailed echocardiographic examination, including M-mode measurement and color Doppler flow mapping to detect the presence and severity of MR was performed. RESULTS: Patients and control subjects were matched for gender, age and left ventricular ejection fraction. Eight (50%) of 16 patients with MVP had MR. Patients with MVP and MR and patients with rheumatic MR had a significantly larger left atrial diameter. Mean log plasma levels of PF4 and BTG were significantly higher in patients with MVP and MR and patients with rheumatic MR than in control subjects (1.17 +/- 0.22 and 0.93 +/- 0.23 IU/ml vs. 0.52 +/- 0.34 IU/ml, p < 0.01; 1.70 +/- 0.21 and 1.53 +/- 0.15 IU/ml vs. 1.37 +/- 0.15 IU/ml, p < 0.05, respectively) but were comparable in patients with MVP and no MR and control subjects. Plasma levels of PF4 and BTG were positively correlated with the severity of MR, as assessed by a semiquantitative method (r = 0.59, p = 0.0001; r = 0.60, p = 0.0001, respectively). Increasing age and left atrial enlargement were not related to platelet activation. CONCLUSIONS: MR in mitral valve disease was associated with systemic platelet activation. MVP itself was not associated with increased platelet activation. The degree of platelet activation was positively correlated with the severity of MR and was independent of the underlying etiology of mitral valve disease, age and left atrial size. The possibility of a higher incidence of thromboembolism and the role of antiplatelet agents in such patients will require further studies to determine.


This article has been cited by other articles:


Home page
HeartHome page
A Boldt, U Wetzel, J Lauschke, J Weigl, J Gummert, G Hindricks, H Kottkamp, and S Dhein
Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease
Heart, April 1, 2004; 90(4): 400 - 405.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Boldt, U. Wetzel, J. Weigl, J. Garbade, J. Lauschke, G. Hindricks, H. Kottkamp, J. F. Gummert, and S. Dhein
Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease
J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1785 - 1792.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
E. Atalar, T. Aqil, K. Aytemir, I. Haznedarolu, N. Ozer, H. Kiliq, G. Kuru, S. Aksdyek, K. Ovtinq, S. Kes, et al.
Diminished Global Fibrinolytic Capacity in Patients With Mitral Valve Prolapse Is Associated With Transient Ischemic Attacks
Clinical and Applied Thrombosis/Hemostasis, January 1, 2002; 8(1): 41 - 44.
[Abstract] [PDF]


Home page
Eur Heart JHome page
S. Kamath, A.D. Blann, and G.Y.H. Lip
Platelets and atrial fibrillation
Eur. Heart J., December 2, 2001; 22(24): 2233 - 2242.
[PDF]


Home page
ChestHome page
D. N. Salem, D. Hartnett Daudelin, H. J. Levine, S. G. Pauker, M. H. Eckman, and J. Riff
Antithrombotic Therapy in Valvular Heart Disease
Chest, January 1, 2001; 119(2009): 207S - 219S.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
H. D. Pedersen and J. Haggstrom
Mitral valve prolapse in the dog: a model of mitral valve prolapse in man
Cardiovasc Res, August 1, 2000; 47(2): 234 - 243.
[Full Text] [PDF]


Home page
StrokeHome page
W. M. Feinberg, L. A. Pearce, R. G. Hart, M. Cushman, E. S. Cornell, G. Y.H. Lip, and E. G. Bovill
Markers of Thrombin and Platelet Activity in Patients With Atrial Fibrillation : Correlation With Stroke Among 1531 Participants in the Stroke Prevention in Atrial Fibrillation III Study
Stroke, December 1, 1999; 30(12): 2547 - 2553.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement